Lessons from the RAMPART study—and which is the best route of administration of benzodiazepines in status epilepticus
dc.contributor.author | Silbergleit, Robert | en_US |
dc.contributor.author | Lowenstein, Daniel | en_US |
dc.contributor.author | Durkalski, Valerie | en_US |
dc.contributor.author | Conwit, Robin | en_US |
dc.date.accessioned | 2013-09-04T17:18:45Z | |
dc.date.available | 2014-10-06T19:17:43Z | en_US |
dc.date.issued | 2013-09 | en_US |
dc.identifier.citation | Silbergleit, Robert; Lowenstein, Daniel; Durkalski, Valerie; Conwit, Robin (2013). "Lessons from the RAMPART study—and which is the best route of administration of benzodiazepines in status epilepticus." Epilepsia : 74-77. <http://hdl.handle.net/2027.42/99698> | en_US |
dc.identifier.issn | 0013-9580 | en_US |
dc.identifier.issn | 1528-1167 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/99698 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Lorazepam | en_US |
dc.subject.other | Emergency Medical Services | en_US |
dc.subject.other | Intramuscular | en_US |
dc.subject.other | Midazolam | en_US |
dc.subject.other | Comparative Efficacy | en_US |
dc.title | Lessons from the RAMPART study—and which is the best route of administration of benzodiazepines in status epilepticus | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/99698/1/epi12284.pdf | |
dc.identifier.doi | 10.1111/epi.12284 | en_US |
dc.identifier.source | Epilepsia | en_US |
dc.identifier.citedreference | U.S. Government Printing Office via GPO Access. ( 2005 ) Exception from informed consent requirements for emergency research. Code of Federal Regulations, [updated 2005; cited 21CFR50.24]; 291‐2]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=50.24 | en_US |
dc.identifier.citedreference | Warden CR, Frederick C. ( 2006 ) Midazolam and diazepam for pediatric seizures in the prehospital setting. Prehosp Emerg Care 10: 463 – 467. | en_US |
dc.identifier.citedreference | Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, Gottwald MD, O'Neil N, Neuhaus JM, Segal MR, Lowenstein DH. ( 2001 ) A comparison of lorazepam, diazepam, and placebo for the treatment of out‐of‐hospital status epilepticus. N Engl J Med 345: 631 – 637. | en_US |
dc.identifier.citedreference | Durkalski V, Silbergleit R, Lowenstein D. ( 2011 ) Challenges in the design and analysis of non‐inferiority trials: a case study. Clin Trials 8: 601 – 608. | en_US |
dc.identifier.citedreference | McMullan J, Sasson C, Pancioli A, Silbergleit R. ( 2010 ) Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta‐analysis. Acad Emerg Med 17: 575 – 582. | en_US |
dc.identifier.citedreference | McMullan JT, Pinnawin A, Jones E, Denninghoff K, Siewart N, Spaite DW, Zaleski E, Silbergleit R; Neurological Emergencies Treatment Trials Investigators. ( 2013 ) The 60‐day temperature‐dependent degradation of midazolam and Lorazepam in the prehospital environment. Prehosp Emerg Care 17: 1 – 7. | en_US |
dc.identifier.citedreference | Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W; NETT Investigators. ( 2012a ) Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 366: 591 – 600. | en_US |
dc.identifier.citedreference | Silbergleit R, Biros MH, Harney D, Dickert N, Baren J. ( 2012b ) Implementation of the exception from informed consent regulations in a large multicenter emergency clinical trials network: the RAMPART experience. Acad Emerg Med 19: 448 – 454. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.